CN115698065A - 艾萨妥昔单抗用于治疗复发性和/或难治性多发性骨髓瘤的用途 - Google Patents

艾萨妥昔单抗用于治疗复发性和/或难治性多发性骨髓瘤的用途 Download PDF

Info

Publication number
CN115698065A
CN115698065A CN202080095185.2A CN202080095185A CN115698065A CN 115698065 A CN115698065 A CN 115698065A CN 202080095185 A CN202080095185 A CN 202080095185A CN 115698065 A CN115698065 A CN 115698065A
Authority
CN
China
Prior art keywords
antibody
individual
seq
amino acid
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095185.2A
Other languages
English (en)
Chinese (zh)
Inventor
M-L·里塞
G·阿赛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Aventis US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis US LLC filed Critical Sanofi Aventis US LLC
Publication of CN115698065A publication Critical patent/CN115698065A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ceramic Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CN202080095185.2A 2019-12-06 2020-12-04 艾萨妥昔单抗用于治疗复发性和/或难治性多发性骨髓瘤的用途 Pending CN115698065A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962944809P 2019-12-06 2019-12-06
US62/944,809 2019-12-06
EP20315186.5 2020-04-17
EP20315186 2020-04-17
US202063023198P 2020-05-11 2020-05-11
US63/023,198 2020-05-11
US202063037353P 2020-06-10 2020-06-10
US63/037,353 2020-06-10
US202063094833P 2020-10-21 2020-10-21
US63/094,833 2020-10-21
PCT/US2020/063468 WO2021113754A1 (en) 2019-12-06 2020-12-04 Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma

Publications (1)

Publication Number Publication Date
CN115698065A true CN115698065A (zh) 2023-02-03

Family

ID=74046182

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095185.2A Pending CN115698065A (zh) 2019-12-06 2020-12-04 艾萨妥昔单抗用于治疗复发性和/或难治性多发性骨髓瘤的用途

Country Status (13)

Country Link
US (1) US20210171653A1 (cg-RX-API-DMAC10.html)
EP (1) EP4069740A1 (cg-RX-API-DMAC10.html)
JP (2) JP7704751B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220159948A (cg-RX-API-DMAC10.html)
CN (1) CN115698065A (cg-RX-API-DMAC10.html)
AU (1) AU2020398655A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010907A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164026A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022009433A2 (cg-RX-API-DMAC10.html)
IL (1) IL293615A (cg-RX-API-DMAC10.html)
MX (1) MX2022006883A (cg-RX-API-DMAC10.html)
TW (2) TWI887310B (cg-RX-API-DMAC10.html)
WO (1) WO2021113754A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153765B2 (en) * 2006-10-19 2012-04-10 Sanof Aventis Anti-CD38 antibodies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) * 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
MX373301B (es) * 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US11618787B2 (en) * 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153765B2 (en) * 2006-10-19 2012-04-10 Sanof Aventis Anti-CD38 antibodies for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THOMAS G. MARTIN ET AL: "Phase III (IKEMA) study design: isatuximab plus carfilzomib and dexamethasone(Kd) vs Kd in patients with relapsed/refractory multiple myeloma(RRMM)", JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15, 1 June 2018 (2018-06-01) *
无: ""NCT03275285" Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)", Retrieved from the Internet <URL:https:clinicaltrials.govstudyNCT03275285tab=history&a=37#version-content-panel> *

Also Published As

Publication number Publication date
MX2022006883A (es) 2022-11-08
JP7704751B2 (ja) 2025-07-08
JP2025138745A (ja) 2025-09-25
WO2021113754A1 (en) 2021-06-10
TWI887310B (zh) 2025-06-21
TW202610683A (zh) 2026-03-16
BR112022010907A2 (pt) 2022-10-18
CO2022009433A2 (es) 2022-07-29
JP2023505219A (ja) 2023-02-08
AU2020398655A1 (en) 2022-07-28
TWI922320B (zh) 2026-04-11
EP4069740A1 (en) 2022-10-12
US20210171653A1 (en) 2021-06-10
TW202133880A (zh) 2021-09-16
IL293615A (en) 2022-08-01
KR20220159948A (ko) 2022-12-05
CA3164026A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
US20250215090A1 (en) Compositions and methods for treating immune thrombocytopenia
JP7712206B2 (ja) 多発性骨髄腫の処置方法
JP2023109927A (ja) ヒトのがんを治療するための特異的抗cd38抗体
JP2023542291A (ja) びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
TW202504915A (zh) 以抗cd3及cd20之雙特異性抗體治療淋巴瘤之方法
CN119730882A (zh) 用于治疗补体介导的疾病的方法
JP2025138745A (ja) 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
TW202541838A (zh) 抗cd38抗體在治療新診斷的多發性骨髓瘤中之用途
KR20250029015A (ko) 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도
WO2023198839A2 (en) Bispecific antibodies against cd3 and cd20
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
CA3048198A1 (en) Methods of treating multiple myeloma
RU2838203C2 (ru) Способы лечения множественной миеломы
WO2026033458A1 (en) DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination